[go: up one dir, main page]

NO20072668L - Ny kombinasjon - Google Patents

Ny kombinasjon

Info

Publication number
NO20072668L
NO20072668L NO20072668A NO20072668A NO20072668L NO 20072668 L NO20072668 L NO 20072668L NO 20072668 A NO20072668 A NO 20072668A NO 20072668 A NO20072668 A NO 20072668A NO 20072668 L NO20072668 L NO 20072668L
Authority
NO
Norway
Prior art keywords
new combination
vaccine directed
neu molecule
quinazolinamines
quinazolinamine
Prior art date
Application number
NO20072668A
Other languages
English (en)
Norwegian (no)
Inventor
Catherine Marie Ghislai Gerard
Claudine Elvire Marie Bruck
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20072668L publication Critical patent/NO20072668L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20072668A 2004-12-10 2007-05-25 Ny kombinasjon NO20072668L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0427131.8A GB0427131D0 (en) 2004-12-10 2004-12-10 Novel combination
PCT/EP2005/013409 WO2006061253A2 (fr) 2004-12-10 2005-12-08 Combinaison

Publications (1)

Publication Number Publication Date
NO20072668L true NO20072668L (no) 2007-09-04

Family

ID=34073534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072668A NO20072668L (no) 2004-12-10 2007-05-25 Ny kombinasjon

Country Status (15)

Country Link
US (1) US20100028414A1 (fr)
EP (1) EP1824509A2 (fr)
JP (1) JP2008523017A (fr)
KR (1) KR20070098857A (fr)
CN (1) CN101115499A (fr)
AU (1) AU2005313439A1 (fr)
BR (1) BRPI0518619A2 (fr)
CA (1) CA2589981A1 (fr)
GB (1) GB0427131D0 (fr)
IL (1) IL183448A0 (fr)
MA (1) MA29133B1 (fr)
MX (1) MX2007006927A (fr)
NO (1) NO20072668L (fr)
RU (1) RU2007120462A (fr)
WO (1) WO2006061253A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7972602B2 (en) 2006-08-11 2011-07-05 Dendreon Corporation Promiscuous HER-2/Neu CD4 T cell epitopes
AU2008205457A1 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
KR20110044905A (ko) * 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
EP2328613A1 (fr) * 2008-08-28 2011-06-08 GlaxoSmithKline Biologicals S.A. Vaccin
WO2012018260A1 (fr) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Thérapie immunitaire ciblant le récepteur du facteur de croissance épidermique
CN107531320B (zh) * 2015-03-19 2021-12-21 威罗门飞行公司 抗机械冲击印刷电路板(pcb)的安装系统
RU2603943C1 (ru) * 2016-02-01 2016-12-10 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ γ-МОДИФИКАЦИЯ N-{3-ХЛОР-4-[(3-ФТОРБЕНЗИЛ)ОКСИ] ФЕНИЛ}-6-[5-({[2-(МЕТАНСУЛЬФОНИЛ)ЭТИЛ]АМИНО}МЕТИЛ)-2-ФУРИЛ]-4-ХИНАЗОЛИНАМИНА БИС (4-МЕТИЛБЕНЗОЛСУЛЬФОНАТА) МОНОГИДРАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
WO2019161209A1 (fr) * 2018-02-15 2019-08-22 Board of Supervisors for the University of Louisiana System Peptidomimétiques ciblant her2 greffés sur des échafaudages peptidiques multicycliques, procédés associés et utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP5164300B2 (ja) * 1999-01-29 2013-03-21 コリクサ コーポレイション ＨＥＲ−２／ｎｅｕ融合タンパク質
KR100815681B1 (ko) * 2000-06-30 2008-03-20 글락소 그룹 리미티드 퀴나졸린 디토실레이트 염 화합물
ATE290882T1 (de) * 2001-01-16 2005-04-15 Glaxo Group Ltd Pharmazeutische mischung gegen krebs, die ein 4- chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
WO2005011607A2 (fr) * 2003-08-01 2005-02-10 Smithkline Beecham Corporation Traitement des cancers exprimant p95erbb2
KR20080014144A (ko) * 2003-08-18 2008-02-13 화이자 프로덕츠 인크. ｅｒｂＢ２ 항암제에 대한 투약 스케쥴

Also Published As

Publication number Publication date
KR20070098857A (ko) 2007-10-05
JP2008523017A (ja) 2008-07-03
IL183448A0 (en) 2007-09-20
WO2006061253A2 (fr) 2006-06-15
CN101115499A (zh) 2008-01-30
MX2007006927A (es) 2007-06-26
US20100028414A1 (en) 2010-02-04
GB0427131D0 (en) 2005-01-12
MA29133B1 (fr) 2008-01-02
BRPI0518619A2 (pt) 2008-11-25
WO2006061253A3 (fr) 2006-11-16
EP1824509A2 (fr) 2007-08-29
CA2589981A1 (fr) 2006-06-15
RU2007120462A (ru) 2009-01-20
AU2005313439A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20072668L (no) Ny kombinasjon
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
CY1111797T1 (el) Τοπικη φαρμακοτεχνικη μορφη ιβερμεκτινης για την θεραπεια δερματολογικων καταστασεων
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
ATE341550T1 (de) Quinolinyl-pyrrolopyrazole
BRPI0507198A (pt) derivados de bisariluréia
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
BR0315580A (pt) Derivados de metileno uréia
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
NO20050204L (no) Kombinasjoner av legemidler for behandling av neoplasmer
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
DK1594885T3 (da) Lægemiddel til vækstinhibering af tumorer
CY1115629T1 (el) Χρηση ενωσεων πεπτιδιου τρο και φαρμακευτικων συνθεσεων στην θεραπεια της αναιμιας
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
MXPA05010020A (es) Derivados de oxamida.
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
BR0316132A (pt) Método para estimular o crescimento de cabelo utilizando benzopiranos
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application